Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Streck CD-Chex™ Plus Immunophenotyping Control
SDP

CD-Chex Plus is a positive procedural control for T-lymphocyte, B-lymphocyte and NK cell enumeration and features two clinically relevant levels of CD4+ cells, a normal level of CD34+ cells and several other parameters for use as leukemia and lymphoma quality controls.

Supplier:  Streck 213370

 View more versions of this product

Catalog No. 23-046-503F


Explore available promotions
Add to Cart
This item is not returnable. View return policy

Description

Description

  • Assayed for 30 parameters, including T-lymphocytes, B-lymphocytes and NK cells.
  • Contains a CD34+ population and is available in two clinically relevant CD4+ levels.
  • Compatible with BD Biosciences and Beckman Coulter flow cytometry systems.
  • 30-day open-vial stability, 90-day closed-vial stability.
  • Manufacturer established assay ranges – no need to verify range per CAP requirements.
  • Access to STATS™, Streck’s free interlaboratory quality control program for peer group data comparison.
Specifications

Specifications

CE
Cap-pierceable Plastic Vial
CD-Chex™ plus Immunophenotyping Control
CD4 Low, Normal
Human Peripheral Blood Leukocytes and Erythrocytes
2°C to 10°C
Beckman Coulter™ flow cytometry system
Immunophenotyping including RBC lysis, Antibody staining, instrument performance and operator technique
10 x 3 mL
3 Months
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.